Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC004087 | Panoply™ Human DCLRE1A Knockdown Stable Cell Line | Inquiry |
| CSC-SC004087 | Panoply™ Human DCLRE1A Over-expressing Stable Cell Line | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD04641Z | Human DCLRE1A adenoviral particles | Inquiry |
| LV10390L | human DCLRE1A (NM_014881) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH275205 | shRNA set against Human DCLRE1A (NM_014881.3) | Inquiry |
| SHH275209 | shRNA set against Mouse DCLRE1A (NM_018831.4) | Inquiry |
| SHH275213 | shRNA set against Rat DCLRE1A (NM_001106201.1) | Inquiry |
| SHW000810 | shRNA set against Chicken DCLRE1A (NM_001008683) | Inquiry |
| SHW008624 | shRNA set against Danio rerio DCLRE1A (NM_001020549) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDFR005961 | Rat Dclre1a cDNA Clone(NM_001106201.1) | Inquiry |
| MiUTR3H-10742 | DCLRE1A miRNA 3'UTR clone | Inquiry |
| CDCB162285 | Chicken DCLRE1A ORF Clone (NM_001008683) | Inquiry |
| CDCB170099 | Danio rerio DCLRE1A ORF Clone (NM_001020549) | Inquiry |
| CDCB182455 | Rabbit DCLRE1A ORF clone (XM_002718753.2) | Inquiry |
| CDCR053920 | Human DCLRE1A ORF clone (NM_014881.3) | Inquiry |
| CDCR253654 | Mouse Dclre1a ORF Clone(NM_018831.4) | Inquiry |
| CDCR372971 | Rat Dclre1a ORF Clone(NM_001106201.1) | Inquiry |
DNA cross-link repair 1A (DCLRE1A) gene is an essential player in the maintenance of genome stability. DCLRE1A belongs to the family of DNA repair genes that are responsible for repairing DNA damage, which can lead to mutations and potentially cause cancer.
The DCLRE1A gene encodes a protein that is involved in the repair of DNA cross-links. DNA cross-links are chemical bonds that form between DNA strands, causing structural and functional abnormalities. These cross-links can result from various environmental and endogenous factors, such as UV radiation, chemotherapy drugs, and reactive oxygen species. The formation of cross-links can lead to DNA damage, which if not repaired, can result in mutations, cell death, or cancer.
The exact mechanism of how DCLRE1A repairs DNA cross-links is still being unraveled. However, it is known that DCLRE1A interacts with other DNA repair proteins and forms a complex that targets the damaged DNA. This complex then processes the cross-linked DNA, enabling the repair of the damage.
Mutations in the DCLRE1A gene have been associated with various diseases, including cancer, developmental disorders, and neurodegenerative diseases. In cancer, defects in DNA repair mechanisms can lead to unrepaired DNA damage, enabling the accumulation of mutations and promoting tumorigenesis. Impairment of DCLRE1A function has been implicated in the development of various types of cancer, including breast, colon, and prostate cancer.
In addition to cancer, defects in DCLRE1A have been linked to developmental disorders such as cataracts, microcephaly, and growth retardation. Furthermore, DCLRE1A has been implicated in neurodegenerative diseases such as Alzheimer's disease and Huntington's disease. The exact role of DCLRE1A in these diseases is not fully understood, but it is believed that defects in DNA repair can contribute to the accumulation of toxic proteins and mutations, leading to cellular dysfunction and ultimately disease progression.
The study of DCLRE1A has gained significant attention in recent years, leading to the identification of new therapeutic targets and approaches for the treatment of various diseases. For example, researchers have discovered that DCLRE1A is a target for certain chemotherapeutic agents, which can lead to the inhibition of DNA repair and sensitize cancer cells to treatment. Researchers have been exploring the use of small molecules that modulate DCLRE1A activity for the treatment of various diseases. For instance, the development of small molecules that enhance DCLRE1A activity has shown potential in the treatment of cancer and neurodegenerative diseases. On the other hand, inhibitors of DCLRE1A have also been developed and shown to be effective in preclinical models of cancer and other diseases.
Reference: